GSK, bioCSL to increase flu vaccine deliveries to U.S.

Early signs of the upcoming flu season came this week as three vaccine makers--GlaxoSmithKline ($GSK), Sanofi Pasteur and bioCSL--announced their first shipments of flu shots for the 2015-16 season, with two reporting that they will increase the amount of doses they deliver.

GSK said it'll amp its dose count this year by 5 million to 11 million over last year's 27 million doses, while bioCSL said it plans to ship 18 million doses to the U.S., an increase of 20%. Sanofi Pasteur's initial shipment represents the first of more than 65 million doses it plans to deliver throughout the season.

In a change this year, GSK said it plans to only ship quadrivalent flu vaccines to offer broader protection over the trivalent it had been shipping up until last year.

"With flu a priority focus of our portfolio, we have made a significant investment in customer service upgrades, designed to accelerate delivery timelines to customers," Patrick Desbiens, GSK senior vice president of U.S. vaccines, said in a statement.

The news comes after a flu season that many vaccine producers would rather forget: Efficacy fell off a cliff last year due to a late strain change, leading to the shots being just 19% effective in preventing medical visits. That compared with around 50% over the previous three years.

And, to top it off, GSK in April issued a recall for its remaining Flulaval quadrivalent thimerosal-free vaccines in pre-filled syringes due to potency concerns; the pharma reported a 25% sales increase for its flu vaccines before the recall.

The CDC recommends a yearly influenza immunization for everyone over the age of 6 months. During the 2013-14 season, the agency estimated vaccinations prevented 7.2 million influenza-associated illnesses, 3.1 million medically attended illnesses and 90,000 hospitalizations.

- here's the GSK release
- read the Sanofi Pasteur statement
- see the bioCSL release

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.